Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy of Tyrosine in Restless Legs Syndrome

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2012 by Seton Brain and Spine Institute.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Seton Family of Hospitals
Information provided by (Responsible Party):
Seton Brain and Spine Institute
ClinicalTrials.gov Identifier:
NCT01494766
First received: December 15, 2011
Last updated: May 10, 2012
Last verified: May 2012

December 15, 2011
May 10, 2012
January 2012
May 2012   (final data collection date for primary outcome measure)
International RLS Survey Group (IRLSSG20) Score [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
Use of this survey to be used as a marker for severity of RLS symptoms and therefore efficacy of this medication.
Same as current
Complete list of historical versions of study NCT01494766 on ClinicalTrials.gov Archive Site
  • Clinical global impression-global improvement (CGI-I) scale [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
    Use of the CGI-I scale as a secondary outcome measure to determine severity of RLS symptoms and efficacy of medication.
  • Medical Outcomes Study - Sleep Scale (MOS-SS) [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
    Use of the MOS-SS to determine severity of RLS symptoms and efficacy of medication.
  • Case Report Form [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
    Use of a history and physical examination (limited neurological exam) to be used as a secondary assessment measure of RLS symptom severity and medication efficacy. They will be charted in case report format.
Same as current
Not Provided
Not Provided
 
Efficacy of Tyrosine in Restless Legs Syndrome
Pilot Study of the Efficacy of Tyrosine in Restless Legs Syndrome

Tyrosine is a non essential amino acid that is the precursor of the neurotransmitter, dopamine. Tyrosine is converted into Levodihydrophenylalanine (L-Dopa) and L-Dopa is subsequently and avidly converted into dopamine. It is well known that dopamine deficiency leads to the manifestations of restless legs syndrome (RLS). Studies have shown dopamine agonists and L-dopa to be effective in controlling symptoms. No studies to date have been done to determine the role of tyrosine in RLS. This open-label pilot study aims to determine the efficacy and tolerability of tyrosine in RLS, as current agents have limitations in treating RLS in addition to adding another possible agent to the investigators arsenal of treating RLS that maybe more cost efficient. In this pilot study, the dose of tyrosine will be escalated from 750 mg once daily by mouth (PO) up to 3000 mg once daily PO, as tolerated, in increments of 750 mg every week in patients who meet the inclusion criteria for RLS. Patients' symptoms will be monitored on a weekly basis for six weeks.

Not Provided
Interventional
Not Provided
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Restless Legs Syndrome (RLS)
Dietary Supplement: L-Tyrosine
L-Tyrosine 750 mg PO every day for 7 days, then increase to 1500 mg PO every day for 7 days, then increase to 2250 mg PO every day for 7 days, then increase to 3000 mg PO every day for remainder of the study.
Other Name: NOW Brand L-Tyrosine 750 mg Tablets
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
5
May 2012
May 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Men and women aged 18 to 80 years and
  2. Newly diagnosed (medication-naïve) as having restless legs syndrome (using the International Restless Legs Syndrome Study Group (IRLSSG20) diagnostic criteria with a score of greater than or equal to 15, see Appendix A) and
  3. That interfered with sleep onset and/or maintenance for greater than four nights/week for a minimum of six months
  4. Currently not receiving treatment for RLS

Exclusion Criteria:

  1. Patients suffering from secondary RLS (other movement and/or primary sleep disorders, chronic renal insufficiency - calculated from the creatinine clearance, and/or iron deficiency - baseline serum ferritin level less than 10 ng/ml)
  2. Patients currently on pharmacotherapy for RLS (not medication-naïve) or previous use of pharmacotherapy for RLS in the past
  3. Patients that are pregnant and/or breastfeeding
  4. Patients that are on levothyroxine or monoamine oxidase inhibitors
Both
18 Years to 80 Years
Yes
Contact: Hanul Bhandari, MD 5123247890 hbhandari@seton.org
Contact: Jason Shen, MD 5123247890 jshen@seton.org
United States
 
NCT01494766
CR-11-146
No
Seton Brain and Spine Institute
Seton Brain and Spine Institute
Seton Family of Hospitals
Not Provided
Seton Brain and Spine Institute
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP